MitoQ (mitochondria-targeted antioxidant)

nad mitochondrialinflammation redox

In clinical trials in 3 of 9 markets tracked.

1 randomized trial (22 people, 12 weeks). It improved its main endpoint, a blood or epigenetic marker.

Doses studied: 20 mg/day.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (5)

T6 Broome 2025 MitoQ supplementation does not impact redox responses to acute exercise in skeletal muscle of older individuals doi:10.1016/j.redox.2025.103927
T3 Jeong 2021 Effects of Treadmill Exercise and MitoQ on Mitochondrial Dynamics, Inflammation, and Cognitive Function in D-Galactose-Induced Aging Rats doi:10.3390/brainsci11020164
T3 Young 2019 The mitochondria-targeted antioxidant MitoQ inhibits memory loss, neuropathology, and extends lifespan in aged 3xTg-AD mice doi:10.1016/j.mcn.2019.103409
T3 Al-Zubaidi 2020 Mitochondria-targeted therapeutics, MitoQ and BGP-15, reverse aging-associated meiotic spindle defects in mouse and human oocytes doi:10.1093/humrep/deaa300
TX Braakhuis 2018 The Effect of MitoQ on Aging‐Related Biomarkers: A Systematic Review and Meta‐Analysis doi:10.1155/2018/8575263